Study on Sildenafil and Fetal Growth Restriction

Understanding Fetal Growth Restriction

A recent study investigated whether sildenafil could reduce the incidence and complications associated with severe fetal growth restriction (FGR). FGR is characterized by inadequate fetal growth, which may arise from various maternal health issues or external factors. Conditions such as inflammatory bowel disease, renal disease, and congenital heart defects are known to contribute to FGR. Additionally, genetic abnormalities, intrauterine infections like rubella, and maternal substance use can also lead to poor fetal growth. In cases without identifiable medical conditions, factors such as poverty or inadequate caregiver-child interactions may play a significant role.

Complications of Early Onset Fetal Growth Restriction

Early onset FGR is linked to numerous complications, including necrotizing enterocolitis, which involves the death of intestinal tissue, respiratory issues that can affect fetal oxygen levels, and potential neuro-disabilities. These medical challenges can ultimately result in fetal or neonatal death. Managing such cases can be complex, as physicians must carefully determine the optimal duration for maintaining the fetus in utero to minimize post-delivery complications. While extending the gestation period can enhance survival rates by approximately 2% per day, excessively prolonging the pregnancy may create an unfavorable environment for the fetus.

Investigating Sildenafil’s Potential Benefits

Research Background

In response to this challenge, Sharp and colleagues conducted a study aimed at identifying methods to prevent the uterus from becoming hostile to fetal development. Their findings were published in a 2018 edition of The Lancet Child & Adolescent Health. The researchers focused on the arteries supplying the uterus and hypothesized that maintaining their dilation could help preserve uterine health and prevent FGR. Sildenafil, an enzyme phosphodiesterase inhibitor, was the drug selected for this purpose.

Study Design and Methodology

In a randomized, placebo-controlled, double-blind clinical trial, Sharp and colleagues assigned 70 women to receive sildenafil and 65 women to receive a placebo. The study took place from November 21, 2014, to July 6, 2016, across 19 fetal medicine units in the United Kingdom. Key metrics such as live births, fetal deaths, neonatal deaths, and birth weights were assessed to evaluate the trial’s success.

Results of the Sildenafil Study

No Significant Improvement Observed

The study results indicated no notable differences in the assessed parameters between the sildenafil and placebo groups. The researchers found that the variations in outcomes, including live births, fetal deaths, neonatal deaths, and birth weights, were minimal. Consequently, they concluded that sildenafil did not enhance fetal growth rates or prolong pregnancies.

Implications and Future Directions

Despite the disappointing findings, which contrasted with the theoretical benefits of sildenafil, researchers are prompted to explore alternative markers and factors that may contribute to improved outcomes for severe fetal growth restriction.

Reference

Sharp, A., Cornforth, C., Jackson, R., Harrold, J., Turner, M. A., Kenny, L. C., … & Papageorghiou, A. T. (2017). Maternal sildenafil for severe fetal growth restriction (STRIDER): a multicentre, randomised, placebo-controlled, double-blind trial. The Lancet Child & Adolescent Health.